Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age.

Autor: Díez-Domingo J; Vaccine Research Department, FISABIO Public Health, Valencia, Spain., Sáez-Llorens X; Department of Infectious Diseases, Hospital del Niño Dr José Renán Esquivel and Cevaxin Clinical Research Center, Panama City, Panama.; National Investigation System, Senacyt, Panama City, Panama., Rodriguez-Weber MA; Department of Neonatology, Instituto Nacional de Pediatría, Mexico City, Mexico., Epalza C; Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain.; Research and Clinical Trials Unit, Madrid, Spain.; Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain.; RITIP (Traslational Research Network in Pediatric Infectious Diseases), Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Madrid, Spain., Chatterjee A; Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA., Chiu CH; Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University Taoyuan, Taoyuan, Taiwan., Lin CY; Department of Pediatrics, Hsinchu Mackay Memorial Hospital, Hsinchu City, Taiwan., Berry AA; Department of Pediatrics and Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA., Martinón-Torres F; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.; Genetics, Vaccines, Infectious Diseases and Pediatrics Research Group, Spain, Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Galicia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Baquero-Artigao F; Hospital Universitario Infantil La Paz, Department of Infectious Diseases and Tropical Pediatrics, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain., Langley JM; Canadian Center for Vaccinology, Iwk Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Canada., Ramos Amador JT; Departamento De Salud Pública Y Materno-infantil, Hospital Universitario Clínico San Carlos, Madrid, Spain., Domachowske JB; Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York, USA., Huang LM; Department of Pediatrics, National Taiwan University Hospital, Taipei City, Taiwan., Chiu NC; Department of Pediatrics, Mackay Memorial Hospital, Taipei City, Taiwan., Esposito S; Pietro Barilla Children's Hospital, University of Parma, Pediatric Clinic, Parma, Italy., Moris P; GSK, Rixensart, Belgium., Lien-Anh Nguyen T; GSK, Wavre, Belgium., Nikic V; GSK, Rockville, Maryland, USA., Woo W; GSK, Rockville, Maryland, USA., Zhou Y; GSK, Rockville, Maryland, USA., Dieussaert I; GSK, Rockville, Maryland, USA., Leach A; GSK, Rockville, Maryland, USA., Gonzalez Lopez A; GSK, Rockville, Maryland, USA., Vanhoutte N; GSK, Rixensart, Belgium.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2023 May 29; Vol. 227 (11), pp. 1293-1302.

Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.

Autor: Rodriguez Weber MA; From the *Instituto Nacional De Pediatría, Mexico City, Mexico; †GlaxoSmithKline Vaccines, Wavre, Belgium; ‡Centro Medico Adolfo Lopez Mateos, Toluca, Mexico; and §GlaxoSmithKline Vaccines, King of Prussia, Philadelphia, PA., Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M

Publikováno v: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2014 Dec; Vol. 33 (12), pp. 1262-9.